Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients
Sonnal Lohia1,2, Justyna Siwy3, Emmanouil Mavrogeorgis2,3, Susanne Eder4, Stephanie Thoeni4, Gert Mayer4, Harald Mischak3, Antonia Vlahou1 and Vera Jankowski2*
1Center of Systems Biology, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; slohia@bioacademy.gr (S.L.); vlahoua@bioacademy.gr (A.V.)
2Institute for Molecular Cardiovascular Research, RWTH Aachen University Hospital, 52074 Aachen, Germany; mavrogeorgis@mosaiques.de (E.M.); vjankowski@ukaachen.de (V.J.)
3Mosaiques Diagnostics GmbH, 30659 Hannover, Germany; siwy@mosaiques-diagnostics.com (J.S.); mischak@mosaiques.de (H.M.)
4Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria; susanne.eder@i-med.ac.at (S.E.); stefanie.thoeni@i-med.ac.at (S.T.); gert.mayer@i-med.ac.at (G.M.)
*Correspondence: vjankowski@ukaachen.de; Tel.: +49-(0241)-80-80580; Fax: +49-0241